Claims for Patent: 10,105,313

Summary for Patent: 10,105,313

Title:	Uses of rose pigment compounds
Abstract:	An object of the present invention is to provide hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, and collagen synthesis promoters that contain as an active component one or more pigment compounds that are obtained as extracted from plants of the family Rosaceae, as well as agents for cutaneous application, skin cosmetics, and quasi-drugs that contain such pigment compounds. The present invention provides hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, collagen synthesis promoters, agents for cutaneous application, skin cosmetics, and quasi-drugs that contain one or more compounds in a class of rosacyanins or one or more compounds in a class of rosadelphins as an active component.
Inventor(s):	Fukui; Yuko (Osaka, JP), Yoshimoto; Yuko (Osaka, JP), Matsuoka; Tatsuo (Osaka, JP), Kitagawa; Sayuri (Osaka, JP)
Assignee:	SUNTORY HOLDINGS LIMITED (Osaka-shi, Osaka, JP)
Application Number:	15/311,612
Patent Claims:	1. A method of inhibiting hyaluronidase, comprising administering an effective amount of, as an active component, one or more compounds selected from the group consisting of a compound in a class of rosacyanins as represented by the following general formula (I): ##STR00025## [where R.sub.1 and R.sub.2, taken together, form --O--; or alternatively, R.sub.1 is the following group (a): ##STR00026## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} or the following group (b): ##STR00027## and R.sub.2 is OH]; and a compound in a class of rosadelphins as represented by the following general formula (II): ##STR00028## {where R.sub.1 is the following formula (a): ##STR00029## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} and R.sub.2 is OH; or R.sub.1 and R.sub.2, taken together, form --O--; or R.sub.1 is the following group (b): ##STR00030## and R.sub.2 is --OH}, to a subject in need thereof. 2. The method according to claim 1, wherein the compound in the class of rosacyanins is one or more compounds selected from the group consisting of rosacyanin A1 represented by the following formula: ##STR00031## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosacyanin A2 represented by the following formula: ##STR00032## and rosacyanin B represented by the following formula: ##STR00033## 3. The method according to claim 1, wherein the compound in the class of rosacyanins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosacyanins. 4. The method according to claim 3, wherein the plant of the family Rosaceae that contains the compound in the class of rosacyanins is one or more plants of the family Rosaceae as selected from the group consisting of Madame Violet, Purple Rain, Lavande, Manhattan Blue, Chantilly Lace, Blue Moon, Tasogare, Charles de Gaulle, Violet Dolly, Blue Ribbon, Aozora, Lady X, Blue Bajou, and Sterling Silver. 5. The method according to claim 1, wherein the compound in the class of rosadelphins is one or more compounds selected from the group consisting of rosadelphin A1 represented by the following formula: ##STR00034## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosadelphin A2 represented by the following formula: ##STR00035## and rosadelphin B represented by the following formula: ##STR00036## 6. The method according to claim 1, wherein the compound in the class of rosadelphins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosadelphins. 7. The method according to claim 6, wherein the plant of the family Rosaceae that contains the compound in the class of rosadelphins is a plant of the family Rosaceae that contains the flavonoid 3', 5'-hydroxylase gene. 8. The method according to claim 1, wherein administration of said one or more compounds suppresses matrix metalloproteinase 1 (MMP-1) production. 9. The method according to claim 1, wherein administration of said one or more compounds promotes collagen synthesis. 10. The method according to claim 1, wherein administration of said one or more compounds is cutaneous administration. 11. A method of inhibiting collagenase, comprising administering an effective amount of, as an active component, one or more compounds selected from the group consisting of a compound in a class of rosacyanins as represented by the following general formula (I): ##STR00037## [where R.sub.1 and R.sub.2, taken together, form --O--; or alternatively, R.sub.1 is the following group (a): ##STR00038## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} or the following group (b): ##STR00039## and R.sub.2 is --OH]; and a compound in a class of rosadelphins as represented by the following general formula (II): ##STR00040## {where R.sub.1 is the following formula (a): ##STR00041## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} and R.sub.2 is --OH; or R.sub.1 and R.sub.2, taken together, form --O--; or R.sub.1 is the following group (b): ##STR00042## and R.sub.2 is --OH}, to a subject in need thereof. 12. The method according to claim 11, wherein the compound in the class of rosacyanins is one or more compounds selected from the group consisting of rosacyanin A1 represented by the following formula: ##STR00043## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosacyanin A2 represented by the following formula: ##STR00044## and rosacyanin B represented by the following formula: ##STR00045## 13. The method according to claim 11, wherein the compound in the class of rosacyanins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosacyanins. 14. The method according to claim 13, wherein the plant of the family Rosaceae that contains the compound in the class of rosacyanins is one or more plants of the family Rosaceae as selected from the group consisting of Madame Violet, Purple Rain, Lavande, Manhattan Blue, Chantilly Lace, Blue Moon, Tasogare, Charles de Gaulle, Violet Dolly, Blue Ribbon, Aozora, Lady X, Blue Bajou, and Sterling Silver. 15. The method according to claim 11, wherein the compound in the class of rosadelphins is one or more compounds selected from the group consisting of rosadelphin A1 represented by the following formula: ##STR00046## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosadelphin A2 represented by the following formula: ##STR00047## and rosadelphin B represented by the following formula: ##STR00048## 16. The method according to claim 11, wherein the compound in the class of rosadelphins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosadelphins. 17. The method according to claim 16, wherein the plant of the family Rosaceae that contains the compound in the class of rosadelphins is a plant of the family Rosaceae that contains the flavonoid 3', 5'-hydroxylase gene. 18. The method according to claim 11, wherein administration of said one or more compounds suppresses matrix metalloproteinase 1 (MMP-1) production. 19. The method according to claim 11, wherein administration of said one or more compounds promotes collagen synthesis. 20. The method according to claim 11, wherein administration of said one or more compounds is cutaneous administration. 21. A method of inhibiting elastase, comprising administering an effective amount of, as an active component, one or more compounds selected from the group consisting of a compound in a class of rosacyanins as represented by the following general formula (I): ##STR00049## [where R.sub.1 and R.sub.2, taken together, form --O--; or alternatively, R.sub.1 is the following group (a): ##STR00050## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} or the following group (b): ##STR00051## and R.sub.2 is --OH]; and a compound in a class of rosadelphins as represented by the following general formula (II): ##STR00052## {where R.sub.1 is the following formula (a): ##STR00053## {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms} and R.sub.2 is --OH; or R.sub.1 and R.sub.2, taken together, form --O--; or R.sub.1 is the following group (b): ##STR00054## and R.sub.2 is --OH}, to a subject in need thereof. 22. The method according to claim 21, wherein the compound in the class of rosacyanins is one or more compounds selected from the group consisting of rosacyanin A1 represented by the following formula: ##STR00055## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosacyanin A2 represented by the following formula: ##STR00056## and rosacyanin B represented by the following formula: ##STR00057## 23. The method according to claim 21, wherein the compound in the class of rosacyanins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosacyanins. 24. The method according to claim 23, wherein the plant of the family Rosaceae that contains the compound in the class of rosacyanins is one or more plants of the family Rosaceae as selected from the group consisting of Madame Violet, Purple Rain, Lavande, Manhattan Blue, Chantilly Lace, Blue Moon, Tasogare, Charles de Gaulle, Violet Dolly, Blue Ribbon, Aozora, Lady X, Blue Bajou, and Sterling Silver. 25. The method according to claim 21, wherein the compound in the class of rosadelphins is one or more compounds selected from the group consisting of rosadelphin A1 represented by the following formula: ##STR00058## {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of .alpha.- and .beta.-forms}, rosadelphin A2 represented by the following formula: ##STR00059## and rosadelphin B represented by the following formula: ##STR00060## 26. The method according to claim 21, wherein the compound in the class of rosadelphins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosadelphins. 27. The method according to claim 26, wherein the plant of the family Rosaceae that contains the compound in the class of rosadelphins is a plant of the family Rosaceae that contains the flavonoid 3', 5'-hydroxylase gene. 28. The method according to claim 21, wherein administration of said one or more compounds suppresses matrix metalloproteinase 1 (MMP-1) production. 29. The method according to claim 21, wherein administration of said one or more compounds promotes collagen synthesis. 30. The method according to claim 21, wherein administration of said one or more compounds is cutaneous administration.

Details for Patent 10,105,313

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2034-05-19
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2034-05-19
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2034-05-19
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2034-05-19